Bone turnover 18 months after a single intravenous dose of zoledronic acid
- 10 May 2007
- journal article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 61 (6), 1058-1062
- https://doi.org/10.1111/j.1742-1241.2007.01392.x
Abstract
Zoledronic acid inhibits bone resorption for up to 12 months. It is not known whether the duration of this antiresorptive effect extends beyond this period of time. The aim of this study was to evaluate the changes in bone turnover at 12 months (T12) and 18 months (T18) after a single injection of 4 mg of zoledronic acid. It is a prospective, longitudinal study, with a follow-up for 18 months. We studied male and female patients (60.5 +/- 11.0 years old), with low bone mineral density (BMD) coming from the outpatient clinic in a metabolic bone unit of a tertiary care hospital. All patients received a single intravenous dose of 4 mg of zoledronic acid, bone turnover markers [serum carboxyterminal telopeptide of type I collagen (CTX-I), bone-specific alkaline phosphatase (BSAP)] and BMD [lumbar spine (LS) and total hip (TH)] were measured at baseline, and after 12 months (T12) and 18 months (T18). Median serum CTX-I and BSAP levels were suppressed at T12 in comparison with baseline values: 0.183 to 0.039 ng/ml for CTX-I (p = 0.0002) and 16.95 to 13.96 U/l for BSAP (p = 0.005). At T18, both CTX-I and BSAP continued to be suppressed below baseline at 0.108 ng/ml and 12.23 U/l (p = 0.009 and p = 0.02, vs. T0). Significant increases in BMD at T18 as compared with T12 were observed in patients (median increase 6.1% for LS and 2.0% for TH). Zoledronic acid inhibits bone turnover effectively for 12 months, with evidence for continued suppression and gains in BMD even after 18 months.Keywords
This publication has 14 references indexed in Scilit:
- Determinants of structure–function relationships among bisphosphonatesBone, 2007
- Osteonecrosis of the Jaw — Do Bisphosphonates Pose a Risk?New England Journal of Medicine, 2006
- Osteonecrosis of the Jaw: More Research NeededJournal of Bone and Mineral Research, 2006
- Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerging role of intermittent therapyClinical Therapeutics, 2005
- Severely Suppressed Bone Turnover: A Potential Complication of Alendronate TherapyJournal of Clinical Endocrinology & Metabolism, 2005
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Measurement of Bone Degradation Products in Serum Using Antibodies Reactive with an Isomerized Form of an 8 Amino Acid Sequence of the C-Telopeptide of Type I CollagenJournal of Bone and Mineral Research, 1997
- Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post‐menopausal osteoporosisClinical Endocrinology, 1997
- Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.Journal of Clinical Endocrinology & Metabolism, 1995